Physician

Internal Medicine

Dr. Helmut G. Schrott, MD

Helmut G. Schrott, MD is an expert in the field of Internal Medicine. Helmut Schrott is also a published doctor. He has 60 paper published. The most recent paper is: Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary ...

Publications

Comparison of the Heart and Estrogen/Progestin Replacement Study (HERS) cohort with women with coronary disease from the National Health and Nutrition Examination Surv...
Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease.
Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia.
Model workshop on nutrition counseling for dietitians.
Recruitment by screening entire communities. The Iowa Lipid Research Clinic Experience.
The Muscatine Cholesterol Family Study: distribution of cholesterol levels within families of probands with high, low and middle cholesterol levels.
The Muscatine Cholesterol Family Study: familial aggregation of blood lipids and relationship of lipid levels to age, sex and hormone use.
Coronary artery disease mortality in relatives of hypertriglyceridemic school children: the Muscatine study.
Multivariate models for human genetic analysis: aggregation, coaggregation, and tracking of systolic blood pressure and weight.
Coronary prevention study yields proof of cholesterol link.
Effect of spouse support and health beliefs on medication adherence.
Calcium infusion and phosphate deprivation tests in patients with primary hyperparathyroidism and with normocalcemia and nephrolithiasis.
Familial hypercholesterolemia in a large indred. Evidence for a monogenic mechanism.
Study of the incidence of hypospadias in Rochester, Minnesota, 1940-1970, and a case-control comparison of possible etiologic factors.
The interaction of familial and secondary causes of hypertriglyceridemia: role in pancreatitis.
Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia.
Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction.
Prenatal prediction in myotonic dystrophy: guidelines for genetic counseling.
Plasma lipid levels and coronary heart disease in adult relatives of newborns with normal and elevated cord blood lipids.
Genetics of hyperlipidemia in coronary heart disease.
Linkage studies in a large kindred with familial hypercholesterolemia.
The cholesterol hypothesis and the coronary primary prevention trial.
Translocation, t(4qminus;13qplus), in three generations resulting in partial trisomy of the long arm of chromosome 4 in the fourth generation.
Aggregation of blood pressure in the families of children with labile high systolic blood pressure. The Muscatine Study.
Managing lipid disorders.
Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing.
Myocardial infarction in the familial forms of hypertriglyceridemia.
Myotonic dystrophy: opportunities for prenatal prediction.
Increased coronary mortality in relatives of hypercholesterolemic school children: the Muscatine study.
Tracking of blood lipids and blood pressures in school age children: the Muscatine study.
The Muscatine hyperlipidemia family study program.
Cardiac, skeletal and ophthalmologic abnormalities in relatives of patients with the Marfan syndrome.
Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy.
Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HER...
Factors associated with glucose and insulin levels in healthy postmenopausal women.
Effect of atorvastatin on blood lipid levels in the first 2 weeks of treatment: a randomized, placebo-controlled study.
Improving prevention systems in primary care practices: the Health Education and Research Trial (HEART)
Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simv...
Effect of hormone replacement therapy on the validity of the Friedewald equation in postmenopausal women: the postmenopausal estrogen/progestins interventions (PEPI) t...
The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and f...
Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary ...
Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions.
Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group.
Once-daily, extended-release gemfibrozil in patients with dyslipidemia. The Lopid SR Work Group I.
Strenuous physical activity, treadmill exercise test performance and plasma high-density lipoprotein cholesterol. The Lipid Research Clinics Program Prevalence Study.
The cholesterol controversy.
Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia.
Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia.
Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia.
Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions.
Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.
Statin pleiotropy: a popular concept but clinical significance unclear.
Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis.
Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treat...
Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis.
Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol.
Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia.
Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS).

Schools

State University of New York At Buffalo

Doctors Specialties

Internal Medicine

Accepted Insurances

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Margo L. Schilling, MD This Doctor is OpenDoctor Recommended.
	Dr. Kristen A. Saehler, DO This Doctor is OpenDoctor Recommended.
	Dr. Sameet S. Sangha, MD